The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

U.S. President Donald Trump listens to remarks during a swearing-in ceremony for Administrator of the Centers for Medicare ...

A move to offer costly weight-loss drugs for obese Americans on Medicare and Medicaid may be in the works, but such a program ...

The federal government's Medicare program and older adults together spend $4.4 billion a year on care that has low clinical ...

Trump is changing Medicare, mostly focusing on providers. But the biggest impact may come from tariffs and deporting ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Working seniors need professional advice when making coverage decisions, but only 21% of retirees with advisers receive ...

Thousands of Rhode Island seniors and disabled residents no longer covered for non-emergency visits at four local hospitals ...

Medicare drug plans are increasingly excluding coverage of new specialty drugs that treat complex conditions like cancers and ...